Crossmark

Time for new imaging and therapeutic approaches in cardiac amyloidosis

Crossref DOI link: https://doi.org/10.1007/s00259-019-04325-4

Published Online: 2019-04-23

Published Print: 2019-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Slart, Riemer H. J. A.

Glaudemans, Andor W. J. M.

Noordzij, Walter

Bijzet, Johan

Hazenberg, Bouke P. C.

Nienhuis, Hans L. A.
License Information

Text and Data Mining valid from 2019-04-23
More Information

Article History

Received: 20 March 2019

Accepted: 31 March 2019

First Online: 23 April 2019

Compliance with ethical standards

:

: Riemer H.J.A. Slart declares that he has no conflict of interest. Andor W.J.M. Glaudemans declares that he has no conflict of interest. Walter Noordzij declares that he has no conflict of interest. Johan Bijzet declares that he has no conflict of interest. Bouke P.C. Hazenberg received some consultancy fees from Pfizer and Alnylam. Hans L. A. Nienhuis received some consultancy fees from Pfizer and Alnylam.

: This article does not contain any studies with human participants performed by any of the authors.

Free to read: This content has been made available to all.